BIIB
BIIBXNAS

Biogen Inc. Common Stock

Market cap $29.9B

$202.19

+72.91 (+56.40%)past year

BIIB

$202.19

+0.78% today

Market price$202.19
Shares1
Est. total$202.19

Buy with €1M virtual cash · No real money

Biogen Inc. Common Stock (BIIB) is a publicly traded company listed on the XNAS. As of July 27, 2026, Invest's signal rates BIIB a Buy, with the stock up 54% over the past year. You can practice trading BIIB risk-free with €1,000,000 in virtual cash.

Key stats

As of July 27, 2026

Market Cap

$29.9B

Volume

596K

52-wk High

$219.72

52-wk Low

$124.56

Day High

$203.30

Day Low

$200.04

P/E (TTM)

21.74

Revenue (TTM)

$9.9B

EPS (TTM)

$9.30

Performance

1M

+1.3%

6M

+16.3%

1Y

+54.4%

Invest signal · BIIB

Buy
SellHoldBuy
1-year trend+54%
3-month momentum+8%
Valuation (P/E)21.7
Revenue growth (QoQ)+8.7%
Profitability (EPS)Profitable

Algorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.

BIIB overview

AI overview

Revenue & EPS — last 8 quarters

QoQ rev +8.7%

Revenue

$2B
Q1 '24
Q2 '24
Q3 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26

EPS (diluted)

$2.15 per share
Q1 '24
Q2 '24
Q3 '24
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Q1 '26

About Biogen Inc. Common Stock

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus.

Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Employees

7,500

www.biogen.com

30-Day Win Rate · BIIB

52%WIN RATE
Up days

12 days

Down days

11 days

Last 23 sessions

How to practice trading BIIB

  1. 1

    Use the BIIB buy panel above

    Set a quantity and hit Buy at the real market price — right here, nothing to download.

  2. 2

    Trade with €1,000,000 virtual cash

    You get a million in virtual money instantly to invest, risk-free.

  3. 3

    Create a free account to save it

    Sign up in seconds to keep your portfolio and track its performance.

  4. 4

    Track and compete

    Watch your portfolio grow and climb the global leaderboard — or start a private league.

  5. 5

    Prefer mobile? Get the iOS app

    Invest is also free on the App Store, synced with your web account.

Top BIIB traders on Invest

Full leaderboard
🥇Maya P.+103.0%
🥈mia_invests+90.0%
🥉Emma R.+76.0%
#4Priya S.+64.0%
#5Oscar L.+51.0%

Frequently asked questions

Is BIIB a good stock to buy right now?

As of July 27, 2026, Invest's signal rates BIIB a Buy, based on its price trend, valuation, and fundamentals (P/E around 21.7), with the stock up 54% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading BIIB risk-free first.

What is Biogen Inc. Common Stock's (BIIB) market cap?

Biogen Inc. Common Stock has a market capitalization of approximately $29.9B, on trailing-twelve-month revenue of about $9.9B.

How has BIIB stock performed?

BIIB is up 54% over the past year and up 16% over six months. Its 52-week range runs roughly from $124.56 to $219.72. Past performance doesn't predict future results.

How can I practice trading BIIB for free?

On Invest you get €1,000,000 in virtual cash and can buy BIIB at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.

More stocks to practice

Compare BIIB with peers

Invest — Stock Market SimulatorNot financial advice.